ASTCT to Present Distinguished Honors at the 2024 Tandem Meetings
CHICAGO, IL / ACCESSWIRE / February 22, 2024 / American Society for Transplantation and Cellular Therapy® (ASTCT) presents top awards...
Cancer
Establishment Labs Announces Amended Credit Facility with Oaktree
- Amendment of commercial and regulatory milestones for $50 million of additional non-dilutive capital to support launch of Motiva Implants®...
Establishment Labs Announces Amended Credit Facility with Oaktree
- Amendment of commercial and regulatory milestones for $50 million of additional non-dilutive capital to support launch of Motiva Implants®...
ChristianaCare Improves Care for Black Patients Living with Heart Failure and Hypertension
Digital hybrid platform with dedicated health coaches delivers significant improvements for heart patients; expands to all patients through ChristianaCare’s Center...
ChristianaCare Improves Care for Black Patients Living with Heart Failure and Hypertension
Digital hybrid platform with dedicated health coaches delivers significant improvements for heart patients; expands to all patients through ChristianaCare’s Center...
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55Reports full-year...
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
BERKELEY, Calif. and MAINZ, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a...
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
MedBright AI Announces Limmi Disease Insights Platform Being Used in University Hospital Setting to Improve Detection of Kidney Stone Disease Recurrence
VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF) is...
Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment
Predictive Precision Medicine Platform (PPMP) utilized to enrich program for clinically responding patients and reduce the risk, time, and cost...
American College of Medical Genetics and Genomics Includes OGM in Latest Edition of Technical Laboratory Standards for Solid Tumor Analysis
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) was...
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
Company implementing a series of cost-savings measures designed to extend Salarius’ expected cash runway into the first half of 2025...
Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study
Autonomix Medical, Inc. Clinical Training for First Human Study Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through...
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
- Management will hold a conference call on Thursday, February 29 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 22,...
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
Data Show Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) --...
OncoC4 Announces First Patient with Advanced Prostate Cancer Dosed in Phase 1/2 Trial of BioNTech-partnered BNT316/ONC-392 Program
The Phase 1/2 trial will assess the efficacy and safety of BNT316/ONC-392 in combination with the radioligand therapy lutetium (177Lu)...
Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update
Full year 2023 total revenues of $464.4 million, compared to $250.3 million in 2022 Full year 2023 CAPLYTA net product...
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing...
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
- Submitted New Drug Application (NDA) to US Food and Drug Administration (FDA) for acoramidis for the treatment of transthyretin...
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology...